Special items: Ovarian Cancer and Us blog best viewed in Firefox

Saturday, March 07, 2009

A phase II study of Capecitabine (Xeloda) in the treatment of ovarian cancer resistant or refractory to platinum therapy: MITO-6 trial

negative results trial finding

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.